Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment landscape for hematological malignancies such as relapsed/refractory acute B-cell lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), and multiple myeloma. […]